Metabolism and Disposition of the SGLT2 Inhibitor Bexagliflozin in Rats, Monkeys and Humans.

Metabolism and Disposition of the SGLT2 Inhibitor Bexagliflozin in Rats, Monkeys and Humans. Xenobiotica. 2019 Aug 21;:1-36 Authors: Zhang W, Li X, Ding H, Lu Y, Stilwell GE, Halvorsen YD, Welihinda A Abstract 1. Bexagliflozin is a C-aryl glucoside inhibitor of human sodium-glucose linked transporter 2 (SGLT2) that undergoes oxidation and glucuronidation to form six principal metabolites in humans. 2. In vitro metabolism by human liver microsomes and recombinant enzymes is primarily mediated by CYP3A4 and UGT1A9. Three major oxidation products and three major glucuronides have been identified in vivo. Metabolism by rats is mostly by oxidation whereas metabolism by monkeys and humans is mostly by glucuronidation. Metabolism by monkeys closely resembles metabolism by humans and all metabolites found in humans are also found in monkeys. A greater diversity of metabolites has been identified among human in vivo specimens than among in vitro reaction products. 3. Following oral dosing of humans with 14C-bexagliflozin, the 3'-O-glucuronide contributed 32% of the parent AUC and all other metabolites contributed less than 10%. Of the 91.6% of input radioactivity recovered, 51.1% was in faeces, predominantly as bexagliflozin, and 40.5% was in urine, largely as the 3'-O-glucuronide. Unidentified metabolites contributed 0.27% of the input radiolabel. 4. A quantitative accounting for the metabolism and disposition of bexagliflozin in vivo has be...
Source: Xenobiotica - Category: Research Authors: Tags: Xenobiotica Source Type: research